scispace - formally typeset
S

Sverre E. Kjeldsen

Researcher at University of Oslo

Publications -  771
Citations -  95426

Sverre E. Kjeldsen is an academic researcher from University of Oslo. The author has contributed to research in topics: Blood pressure & Left ventricular hypertrophy. The author has an hindex of 94, co-authored 735 publications receiving 89059 citations. Previous affiliations of Sverre E. Kjeldsen include University of Michigan & Cornell University.

Papers
More filters
Journal ArticleDOI

HDL-cholesterol and prediction of coronary heart disease: modified by physical fitness? A 28-year follow-up of apparently healthy men.

TL;DR: High-density lipoprotein cholesterol (HDL) is a strong predictor of long term risk of CHD, fatal CHD and fatal CVD in healthy middle-aged men and physical fitness or its changes had no impact on the ability of HDL to predict CHD.
Journal ArticleDOI

Circadian variations in blood pressure and their implications for the administration of antihypertensive drugs: is dosing in the evening better than in the morning?

TL;DR: The conclusion is that there is no convincing evidence that the administration of BP-lowering drugs in the evening provides any significant advantage in terms of quality of BP control, prevention of target organ damage or reduction of cardiovascular events.
Journal ArticleDOI

Amlodipine and valsartan: calcium channel blockers/angiotensin II receptor blockers combination for hypertension

TL;DR: The rationale for using multiple-mechanism therapy with the angiotensin receptor blocker valsartan and the calcium channel blocker amlodipine is explored and the clinical data supporting this novel approach to the treatment of hypertension is discussed.
Journal ArticleDOI

Personality may influence reactivity to stress

TL;DR: The present study indicates that stress reactivity is clearly related to different personality traits, without any single trait being dominant over others.
Journal ArticleDOI

A Comparison of the Two β-Blockers Carvedilol and Atenolol on Left Ventricular Ejection Fraction and Clinical Endpoints after Myocardial Infarction

TL;DR: In patients following an acute myocardial infarction, no difference in either global or regional LVEF was observed between baseline and 12 months when treatment with carvedilol was compared with atenolol.